Detected ·
Altay Therapeutics
$37M—
Altay Therapeutics announced the close of a $37M Series A financing, co-led by Sound Bioventures and HealthCap, to advance DX5057, the first oral DUX4 inhibitor, into the clinic for FSHD.
- Website
- —
- linkedin.com/company/69914567
- Amount
- $37 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-15 08:04:39 UTC
- Signal ID
- 8196c38f-86f2-499b-a40f-306cd044ff9e
As the API returns it
{
"id": "8196c38f-86f2-499b-a40f-306cd044ff9e",
"created_at": "2026-10-15T08:04:39.183409Z",
"company_name": "Altay Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/69914567",
"event_type": "funding",
"funding_amount": 37000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Altay Therapeutics announced the close of a $37M Series A financing, co-led by Sound Bioventures and HealthCap, to advance DX5057, the first oral DUX4 inhibitor, into the clinic for FSHD.*"
}